Advertisement

Molecular and Cellular Biochemistry

, Volume 452, Issue 1–2, pp 41–50 | Cite as

The endocrine disruptor bisphenol A promotes nuclear ERRγ translocation, facilitating cell proliferation of Grade I endometrial cancer cells via EGF-dependent and EGF-independent pathways

  • Takahiro YaguchiEmail author
Article
  • 134 Downloads

Abstract

Endocrine disruptors have become a global social and public health problem since the late 1980s. Bisphenol A (BPA) has a steroid-like skeleton similar to estrogen and progesterone, and is an endocrine disruptor that disturbs the physiological hormone balance. The potential involvement of BPA in malignancy of endometrial cancer cells caused by overexposure of steroid hormones remains incompletely understood. The present study aimed at understanding the regulatory mechanism underlying BPA-induced cell proliferation in hormone-sensitive endometrial cancer cells. BPA selectively and significantly induced cell proliferation of Grade I endometrial cancer cells such as HEC265 and Ishikawa cells. In HEC265 and Ishikawa cells, BPA induced nuclear translocation of estrogen-related receptor γ (ERRγ) in a time-dependent manner and increased expression of BPA/ERRγ-target genes. In Ishikawa cells, BPA promoted the influx of Ca2+ followed by epidermal growth factor (EGF) secretion to the extracellular space. Furthermore, EGF secreted from Ishikawa had an autocrine effect, leading to activation of the EGFR/ERK pathway. Contrastingly, in HEC265 cells, BPA increased the expression of BPA/ERRγ-target genes but did not affect Ca2+ mobilization EGF secretion. In conclusion, BPA induced cell proliferation via the BPA/ERRγ/EGF/EGFR/ERK signaling pathway in Ishikawa cells and contrastingly, in HEC265 cells, induced cell proliferation through the BPA/ERRγ signaling pathway.

Keywords

BPA ERRγ EGF Cell proliferation Endometrial cancer cell 

Notes

Acknowledgements

I would like to thank Yoichi Ueta, Yuuki Kamura, Misato Kawahara, Ryosuke Kawamura, Tatsuhiko Sugimoto, Erika Hatakeyama, Ayaka Hosoda, Jumpei Masuwa, Motonobu Mukai, Toshinori Mori, Kanae Ohashi, Saki Ohashi, Mami Ogawa, Suzuka Takahashi, Yui Teruya, Sayaka Fujita, Chisato Akiyama-Yamamuro, Mayu Kajioka, Manami Shiota, Yuri Sugano, Shihoko Sugino, Aoi Chiba, Kazuki Nobuhara, Yuki Matsubara, Syuto Miyake, Ryosuke Yamanaka, Yumi Matsuda, Misaki Mori, and Satoko Kodama for their contributions and helpful discussions. This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

The author declares no conflicts of interest in association with the present study.

Supplementary material

11010_2018_3410_MOESM1_ESM.tif (16.8 mb)
Supplementary Fig. 1 Nuclear translocation of ERRγ is not activated by vehicle treatment. HEC265 and Ishikawa cells were treated with vehicle control for the indicated times. Western blotting was carried out with nuclear and cytoplasmic fractions using anti-ERRγ, anti-Lamin or anti-β-actin antibody (n=3 independent experiments).—Supplementary material 1 (TIF 17230 KB)
11010_2018_3410_MOESM2_ESM.tif (17.5 mb)
Supplementary Fig. 2 BPA does not induce secretion of growth factors aFGF, bFGF, and HGF in HEC265 and Ishikawa cells. Both cell types were treated with BPA or vehicle control for 24 h, and conditioned medium was collected. Conditioned medium was immunoprecipitated with anti-aFGF, anti-bFGF, or anti-HGF antibody and Western blotting was carried out (n=3 independent experiments).—Supplementary material 2 (TIF 17926 KB)
11010_2018_3410_MOESM3_ESM.tif (17 mb)
Supplementary Fig. 3 ERRγ knockdown does not affect the expression of ERRs other than ERRγ in HEC265 and Ishikawa cells. HEC265 and Ishikawa cells were treated with ERRγ siRNA or non-coding control siRNA for 24 h followed by collecting total RNA, and RT-PCR was carried out (n=3 independent experiments).—Supplementary material 3 (TIF 17418 KB)
11010_2018_3410_MOESM4_ESM.tif (17.8 mb)
Supplementary Fig. 4 EGF knockdown did not affect the expression of ERRs in HEC265 and Ishikawa cells. HEC265 and Ishikawa cells were treated with EGF siRNA or non-coding control siRNA for 24 h. Total RNAs were collected 3 h after BPA stimulation and RT-PCR was carried out (b) (n=3 independent experiments). EGF mRNA expression was inhibited by EGF siRNA (a).—Supplementary material 4 (TIF 18208 KB)

References

  1. 1.
    Suarez AA, Felix AS, Cohn DE (2017) Bokhman Redux: endometrial cancer “types” in the 21st century. Gynecol Oncol 144(2):243–249CrossRefGoogle Scholar
  2. 2.
    Krakstad C, Birkeland E, Seidel D, Kusonmano K, Petersen K, Mjøs S, Hoivik EA, Wik E, Halle MK, Øyan AM, Kalland KH, Werner HM, Trovik J, Salvesen H (2012) High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLoS ONE.  https://doi.org/10.1371/journal.pone.0052795 Google Scholar
  3. 3.
    Garcia-Dios DA, Lambrechts D, Coenegrachts L, Vandenput I, Capoen A, Webb PM, Ferguson K, ANECS., Akslen LA, Claes B, Vergote I, Moerman P, Van Robays J, Marcickiewicz J, Salvesen HB, Spurdle AB, Amant F (2013) High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecol Oncol 128(2):327–334CrossRefGoogle Scholar
  4. 4.
    Meng X, Dizon DS, Yang S, Wang X, Zhu D, Thiel KW, Leslie KK (2013) Strategies for molecularly enhanced chemotherapy to achieve synthetic lethality in endometrial tumors with mutant p53. Obstet Gynecol Int.  https://doi.org/10.1155/2013/828165 Google Scholar
  5. 5.
    Lv QY, Xie BY, Yang BY, Ning CC, Shan WW, Gu C, Luo XZ, Chen XJ, Zhang ZB, Feng YJ (2017) Increased TET1 expression in inflammatory microenvironment of hyperinsulinemia enhances the response of endometrial cancer to estrogen by epigenetic modulation of GPER. J Cancer 8(5):894–902CrossRefGoogle Scholar
  6. 6.
    Zhuang Y, Xiang J, Bao W, Sun Y, Wang L, Tan M, He Y, Xi X (2017) MDH2 stimulated by estrogen-GPR30 pathway down-regulated PTEN expression promoting the proliferation and invasion of cells endometrial cancer. Transl Oncol 10(2):203–210CrossRefGoogle Scholar
  7. 7.
    Owens GL, Lawrence KM, Jackson TR, Crosbie EJ, Sayan BS, Kitchener HC, Townsend PA (2017) Urocortin suppresses endometrial cancer cell migration via CRFR2 and its system components are differentially modulated by estrogen. Cancer Med 6(2):408–415CrossRefGoogle Scholar
  8. 8.
    Kajta M, Wójtowicz AK (2013) Impact of endocrine-disrupting chemicals on neural development and the onset of neurological disorders. Pharmacol Rep 65(6):1632–1639CrossRefGoogle Scholar
  9. 9.
    Schug TT, Janesick A, Blumberg B, Heindel JJ (2011) Endocrine disrupting chemicals and disease susceptibility. J Steroid Biochem Mol Biol 127(3–5):204–215CrossRefGoogle Scholar
  10. 10.
    Ünüvar T, Büyükgebiz A (2012) Fetal and neonatal endocrine disruptors. J Clin Res Pediatr Endocrinol. 4(2): 51–60CrossRefGoogle Scholar
  11. 11.
    Pollock T, Weaver RE, Ghasemi R, deCatanzaro D (2017) Butyl paraben and propyl paraben modulate bisphenol A and estradiol concentrations in female and male mice. Toxicol Appl Pharmacol 325:18–24CrossRefGoogle Scholar
  12. 12.
    Ogo FM, Siervo GE, Gonçalves GD, Cecchini R, Guarnier FA, Anselmo-Franci JA, Fernandes GS (2017) Low doses of bisphenol A can impair postnatal testicular development directly, without affecting hormonal or oxidative stress levels. Reprod Fertil Dev.  https://doi.org/10.1071/RD16432 Google Scholar
  13. 13.
    Rattan S, Zhou C, Chiang C, Mahalingam S, Brehm E, Flaws J (2017) Exposure to endocrine disruptors during adulthood: consequences for female fertility. J Endocrinol.  https://doi.org/10.1530/JOE-17-0023 Google Scholar
  14. 14.
    Heindel JJ, Newbold RR, Bucher JR, Camacho L, Delclos KB, Lewis SM, Vanlandingham M, Churchwell MI, Twaddle NC, McLellen M, Chidambaram M, Bryand M, Woodloing K, Gamboa da Costa G, Ferguson SA, Flaws J, Howard PC, Walker NJ, Zoeller RT, Fostel J, Favaro C, Schug TT (2015) NIEHS/FDA CLARITY-BPA research program update. Reprod Toxicol 58:33–44CrossRefGoogle Scholar
  15. 15.
    Schug TT, Heindel JJ, Camacho L, Delclos KB, Howard P, Johnson AF, Aungst J, Keefe D, Newbold R, Walker NJ, Thomas Zoeller R, Bucher JR (2013) A new approach to synergize academic and guideline-compliant research: the CLARITY-BPA research program. Reprod Toxicol 40:35–40CrossRefGoogle Scholar
  16. 16.
    Birnbaum LS, Aungst J, Schug TT, Goodman JL (2013) Working together: research- and science-based regulation of BPA. Environ Health Perspect  https://doi.org/10.1289/ehp.1306963 Google Scholar
  17. 17.
    Liu X, Matsushima A, Shimohigashi M, Shimohigashi Y (2014) A characteristic back support structure in the bisphenol A-binding pocket in the human nuclear receptor ERRγ. PLoS ONE 9(6):e101252.  https://doi.org/10.1371/journal.pone.0101252 CrossRefGoogle Scholar
  18. 18.
    Houari S, Loiodice S, Jedeon K, Berdal A, Babajko S (2016) Expression of steroid receptors in ameloblasts during amelogenesis in rat incisors. Front Physiol 7:503CrossRefGoogle Scholar
  19. 19.
    Liu X, Matsushima A, Shimohigashi M, Shimohigashi Y (2014) A characteristics back support structure in the bisphenol A-binding pocket in the human nuclear receptor ERRγ. PLoS ONE 9(6):e101252.  https://doi.org/10.1371/journal.pone.0101252 CrossRefGoogle Scholar
  20. 20.
    Teeguarden J, Hanson-Drury S, Fisher JW, Doerge DR (2013) Are typical human serum BPA concentrations measurable and sufficient to be estrogenic in the general population? Food Chem Toxicol.  https://doi.org/10.1016/j.fct2013.08.001 Google Scholar
  21. 21.
    Wang KH, Kao AP, Chang CC, Lin TC, Kuo TC (2015) Bisphenol A-induced epithelial to mesenchymal transition is mediated by cyclooxygenase-2 up-regulation in human endometrial cancer cells. Reprod Toxicol.  https://doi.org/10.1016/j.reprotox Google Scholar
  22. 22.
    Qin XY, Fukuda T, Yang L, Zaha H, Akanuma H, Zeng Q, Yoshinaga J, Sone H (2012) Effects of bisphenol A exposure on the proliferation and senescence of normal human mammary epithelial cells. Cancer Biol Ther 13(5):296–306CrossRefGoogle Scholar
  23. 23.
    Kim JH, Choi YK, Do JY, Choi YK, Ha CM, Lee SJ, Jeon JH, Lee WK, Choi HS, Park KG, Lee IK (2015) Estrogen-related receptor γ plays a key role in vascular calcification through the upregulation of BMP2 expression. Arterioscler Thromb Vasc Biol 35(11):2384–2390CrossRefGoogle Scholar
  24. 24.
    Kwon DH, Eom GH, Kee HJ, Nam YS, Cho YK, Kim DK, Koo JY, Kim HS, Nam KI, Kim KK, Lee IK, Park SB, Choi HS, Kook H (2013) Estrogen-related receptor gamma induces cardiac hypertrophy by activating GATA4. J Mol Cell Cardiol 65:88–97CrossRefGoogle Scholar
  25. 25.
    Yang Y, Yang C, Zhang J (2015) C23 protein meditates bone morphogenetic protein-2-mediated EMT via up-regulation of Erk1/2 and Akt in gastric cancer. Med Oncol 32(3):76CrossRefGoogle Scholar
  26. 26.
    Kim DK, Ryu D, Koh M, Lee MW, Lim D, Kim MJ, Kim YH, Cho WJ, Lee CH, Park SB, Koo SH, Choi HS (2012) Orphan nuclear receptor estrogen-related receptor γ (ERRγ) is key regulator of hepatic gluconeogenesis. J Biol Chem 287(26):21628–21639CrossRefGoogle Scholar
  27. 27.
    Majchrzak-Baczmańska D, Malinowski A (2016) Does IGF-1 play a role in the biology of endometrial cancer? Ginekol Pol 87(8):598–604CrossRefGoogle Scholar
  28. 28.
    Chang CC, Ling XH, Hsu HF, Wu JM, Wang CP, Yang JF, Fang LW, Houng JY (2016) Siegesbeckia orientalis extract inhibits TGFβ1-induced migration and invasion of endometrial cancer cells. Molecules.  https://doi.org/10.3390/molecules21081021 Google Scholar
  29. 29.
    Zhang J, Song H, Lu Y, Chen H, Jiang S, Li L (2016) Effects of estradiol on VEGF and bFGF by Akt in endometrial cancer cells are mediated through the NF-κB pathway. Oncol Rep 36(2):705–714CrossRefGoogle Scholar
  30. 30.
    Connor P, Talavera F, Kang JS, Burke J, Roberts J, Menon KM (1997) Epidermal growth factor activates protein kinase C in the human endometrial cancer cell line HEC-1A. Gynecol Oncol 67(1):46–50CrossRefGoogle Scholar
  31. 31.
    Bae-Jump V, Segreti EM, Vandermolen D, Kauma S (1999) Hepatocyte growth factor (HGF) induces invasion of endometrial carcinoma cell lines in vitro. Gynecol Oncol 73(2):265–272CrossRefGoogle Scholar
  32. 32.
    Winterhoff B, Konecney GE (2017) Targeting fibroblast growth factor pathways in endometrial cancer. Curr Probl Cancer 41(1):37–47CrossRefGoogle Scholar
  33. 33.
    Bilancio A, Bontempo P, Donato MD, Conte M, Giovannelli P, Altucci L, Migliaccio A, Castoria G (2017) Bisphenol A induces cell cycle arrest in primary and prostate cancer cells through EGFR/ERK/p53 signaling pathway activation. Oncotarget 8(70):115620–115631CrossRefGoogle Scholar
  34. 34.
    Hao J, Bao X, Jin B, Wang X, Mao Z, Li X, Wei L, Shen D, Wang JL (2015) Ca2+ channel subunit α 1D promotes proliferation and migration of endometrial cancer cells mediated by 17β-estradiol via the G protein-coupled estrogen receptor. FASEB J 29(7):2883–2893CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Chemical Technology, Graduate School of Science and Industrial TechnologyKurashiki University of Science and the ArtsKurashikiJapan
  2. 2.Department of Medical Laboratory Science, Graduate School of Health and Welfare SciencesInternational University of Health and WelfareOkawaJapan

Personalised recommendations